RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Authors

Nicholas Robert

Published

March 8, 2011

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

DOI

10.1200/jco.2010.28.0982

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Authors

Nicholas Robert

Published

March 8, 2011

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

DOI

10.1200/jco.2010.28.0982

Paper

Paper

Paper

Paper

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Supporters

Journal

Topics

DOI

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Supporters

Journal

Topics

DOI